Welcome to
InSingulo

A Swedish life science company providing the most sensitive label-free biosensing technology for drug development, diagnostics, and quality control.

Our origins

InSingulo AB was founded in 2017 after a five-year collaboration between AstraZeneca and Chalmers University exploring the opportunity to overcome today’s challenges of biophysics in drug discovery using single-molecule microscopy. Our method developed giving improved sensitivity, extremely low reagent consumption which proved extremely valuable for currently challenging drug targets. This was especially true for studying membrane proteins in their native environment without compromising on data content and quality.

Our mission

Our mission is to provide the most sensitive and productive biosensing technology for drug development, diagnostics, and quality control. We enable our customers to deliver a high-quality output while securing operational excellence and cost-efficiency. While many methods take target proteins and modify them for the sake of the assay, at InSingulo, we keep proteins in their natural state. We believe that biosensing methods should be adopted to the target, not the other way round. We enable faster access to new and more effective medicines.